Cargando…
Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema in Eyes with Branch Retinal Vein Occlusion with vs Without Glaucoma – Does Glaucoma Affect Visual Outcome in Eyes with BRVO-ME After antiVEGF Injections?
PURPOSE: To compare the therapeutic effects of anti-vascular endothelial growth factor (anti-VEGF) agents in eyes with macular edema associated with branch retinal vein occlusion (BRVO-ME) with glaucoma to those without glaucoma. PATIENTS AND METHODS: This retrospective study was conducted using the...
Autores principales: | Asami, Shin, Sugimoto, Masahiko, Tsukitome, Hideyuki, Kato, Kumiko, Matsubara, Hisashi, Kondo, Mineo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296876/ https://www.ncbi.nlm.nih.gov/pubmed/35872969 http://dx.doi.org/10.2147/OPTH.S356727 |
Ejemplares similares
-
Response to Initial Anti-Vascular Endothelial Growth Factor for Diabetic Macular Edema Is Significantly Correlated with Response to Third Consecutive Monthly Injection
por: Maeda, Satoshi, et al.
Publicado: (2022) -
Suppressed endothelin-1 by anti-VEGF therapy is important for patients with BRVO-related macular edema to improve their vision
por: Kida, Teruyo, et al.
Publicado: (2016) -
Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs
por: Péntek, Márta, et al.
Publicado: (2017) -
Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO
por: Tang, Fen, et al.
Publicado: (2019) -
Reasons for choice of glaucoma surgery in eyes not treated with anti-glaucoma medications
por: Sugihara, Kazunobu, et al.
Publicado: (2022)